CEL-SCI Corporation announced the closing of a best-efforts offering of 1,500,000 shares of its common stock on July 14, 2025. The offering was priced at-the-market under NYSE American rules.
Each share of common stock was sold at an offering price of $3.82 per share, generating total gross proceeds of approximately $5.7 million before deducting placement agent fees and other offering expenses.
The company intends to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and for working capital. This capital infusion is crucial for supporting its ongoing clinical programs and operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.